The power to help reduce the chaos of RSV season is in the palm of your hand *
*
Beyfortus ® reduces the risk of medically attended RSV lower respiratory tract disease ( LRTD ) in infants , inclusive of hospitalisation , by > 70 % ( p < 0.0001 ) for at least 5 months post dose vs placebo . † 1 , 2
†
Medically attended RSV is defined by patients having demonstrated at least one physical exam finding of rhonchi , rales , crackles , or wheeze , AND at least one of the following signs : increased respiratory rate , hypoxemia , clinical signs of severe respiratory disease . 1 , 2
Beyfortus ® is indicated for the prevention of RSV LRTD in neonates and infants entering or during their first RSV season , and children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season . 1
Beyfortus ® is contraindicated in individuals with a history of severe hypersensitivity reactions , including anaphylaxis , to the active substances or to any of the excipients . 1
Adverse reactions reported in clinical trials : rash , injection site reaction , pyrexia ( all uncommon ). 1
This medicinal product is subject to additional monitoring in Australia . This will allow quick identification of new safety information . Healthcare professionals are asked to report any suspected adverse events at www . tga . gov . au / reporting-problems .
Before prescribing Beyfortus ® , scan the QR code to view the full Product Information .
Beyfortus ® is funded by State and Territory governments for eligible infants , as outlined by the local state and territory health departments . For further information on the eligibility criteria , please contact your local state or territory health department . Beyfortus ® is not on the PBS or NIP .
Abbreviations : LRTD : lower respiratory tract disease ; RSV : respiratory syncytial virus .
References : 1 . Beyfortus ® ( nirsevimab ) Australia Product Information . 29-Jul-24 . 2 . Hammitt LL , et al . N Engl J Med . 2022 ; 386 ( 9 ): 837 – 846 & Supplementary Appendix .
Sanofi-aventis Australia pty ltd . ABN 31 008 558 807 . Trading as SANOFI . 12 – 24 Talavera Rd , Macquarie Park , NSW , 2113 . MAT-AU-2500190-1.0-02 / 2025 .